CMPX Compass Therapeutics
Price Chart
Executive Summary
Compass Therapeutics (CMPX) will host a webcast on April 27, 2026, to present topline secondary endpoint data from its Phase 2/3 COMPANION-002 trial of tovecimig in combination with paclitaxel for advanced biliary tract cancer. This data readout is a key near-term catalyst for the company, as it could support further development or regulatory discussions for a novel bispecific antibody in a high-unmet-need indication.
Actionable Insight
Traders should monitor the April 27 webcast for signals on tovecimig’s efficacy and safety, which could drive meaningful volatility. A positive outcome may catalyze re-rating potential in this small-cap oncology stock, while negative or ambiguous data could lead to downside risk.
Key Facts
- Compass Therapeutics will present topline secondary endpoints from the Phase 2/3 COMPANION-002 trial on April 27, 2026.
- The trial evaluates tovecimig (a DLL4 x VEGF-A bispecific antibody) plus paclitaxel in advanced biliary tract cancer (BTC).
- Data will be shared via webcast at 8:00am ET, with replay available for 90 days.
- No primary endpoint results or efficacy/safety data are disclosed in this announcement — only the timing of the upcoming presentation.
Financial Impact
No financial impact until data is released; potential for significant stock movement post-readout depending on results.
Risk Factors
- Secondary endpoints are less definitive than primary endpoints and may not support regulatory approval.
- Bispecific antibodies face competitive and safety challenges; any toxicity signals could weigh on sentiment.
- CMPX is a clinical-stage company with no approved products — valuation is entirely dependent on pipeline execution.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3281064 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
3d ago
|
Institutional Cluster
| $2.00 awaiting T+5 | awaiting T+5 | — | $2.03 (+1.50%) |
|
May 21, 2026
24d ago
|
Press Release
| $2.07 $2.22 | ▲ +7.25% | ▲ +5.57% | $2.03 (−1.93%) |
|
May 5, 2026
5w ago
|
8-K
| $1.95 $1.83 | ▼ −6.15% | ▼ −8.14% | $2.03 (+4.10%) |
|
Apr 29, 2026
6w ago
|
DEFA14A
| $1.67 $1.95 | ▲ +16.77% | ▲ +13.66% | $2.03 (+21.56%) |
|
Apr 27, 2026
6w ago
|
8-K
| $1.79 $1.94 | ▲ +8.38% | ▲ +7.98% | $2.03 (+13.41%) |
|
Apr 27, 2026
6w ago
|
Press Release
| $1.79 $1.94 | ▲ +8.38% | ▲ +7.98% | $2.03 (+13.41%) |
|
Apr 24, 2026
7w ago
|
Press Release
| $1.79 $1.94 | ▲ +8.38% | ▲ +7.98% | $2.03 (+13.41%) |
|
Mar 5, 2026
14w ago
|
8-K / PRESS-RELEASE
| $5.53 $5.19 | ▼ −6.15% | ▼ −3.91% | $2.03 (−63.29%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access